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Antibody-screening methods to detect severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) need 
to be validated. We evaluated SARS-CoV-2 IgG and IgA 
ELISAs in conjunction with the EUROLabworkstation 
(Euroimmun, Lübeck, Germany). Overall specificities 
were 91.9% and 73.0% for IgG and IgA ELISAs, respec-
tively. Of 39 coronavirus disease patients, 13 were IgG 
and IgA positive and 11 IgA alone at sampling. IgGs 
and IgAs were respectively detected at a median of 12 
and 11 days after symptom onset.
Severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) causes coronavirus disease (COVID-19) 
[1]. At time of writing on 22 April 2020, the COVID-19 
pandemic had resulted in approximatively 2.5 million 
reported cases worldwide with over 177,000 deaths [1].
Fast and reliable laboratory diagnostics for SARS-CoV2 
[2-4] are important to support the rapid implementa-
tion of appropriate public health interventions. In the 
acute phase of COVID-19, laboratory diagnostics pri-
marily rely on molecular methods [5,6]. In addition, 
serological assays are now being developed to allow 
epidemiological assessments through serosurveys, as 
well as retrospective diagnosis in targeted groups. The 
need for high quality testing kits suitable for in vitro 
diagnostics (IVD), automated laboratory equipment 
and laboratory information systems (LIS) is urgent. LIS, 
which record, manage, and store data are one of the 
key elements in reliable diagnostics with high through-
put. Here we report on the evaluation of an automated 
serological screening approach for SARS-CoV-2 IgG and 
IgA antibodies.
 
Sample collection for evaluation of SARS-
CoV-2 IgG and IgA assays
We evaluated two commercial kits designed to respec-
tively detect SARS-CoV-2 IgG and IgA antibodies in 
patient samples (CE marked in vitro diagnostic prod-
ucts; SARS-CoV-2 IgG and IgA ELISAs, Euroimmun, 
Lübeck, Germany;  www.euroimmun.com). These 
commercial immunoassays are based on recombi-
nant structural protein (S1) from SARS-CoV-2 and 
the S1-based ELISAs have been set up and tested for 
cross-reactions against other HCoVs [7,8]. In the cur-
rent study, the kits were used in combination with 
the automated EUROLabworkstation (Euroimmun) for 
ELISA analysis with LIS.
To estimate specificity, we retrospectively used a panel 
of 37 patient sera from 15 male and 22 female patients 
(median age: 53 years; range: 5-87) collected in 2019 and 
2020, which were considered negative for SARS-CoV-2. 
Among these, 11 serum samples were from patients 
who had been diagnosed with seasonal human coro-
naviruses (HCoVs: OC43, NL63, 229E) or other respira-
tory viruses by nucleic acid tests (NAT). Four of these 11 
samples, which originated from patients testing posi-
tive for HCoV, had been collected in 2019. The rest were 
from 2020. The four samples from 2019 were assumed 
to be from SARS-CoV-2 negative patients, while all the 
samples obtained in 2020 were from patients who had 
been tested for SARS-CoV-2 nucleic acid and found 
negative. The remaining 26 of the 37 serum samples 
originated from patients who had been diagnosed as 
having adenovirus, enterovirus, influenza A, influenza 
B, parainfluenza, or respiratory syncytial (RSV) virus 
infections, through routine IgG antibody testing in 
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COVID-19: coronavirus disease; F: female; ID: identity; M: male; NA: not applicable.
a Symptom severity based on Siddiqi and Mehra (2020, in press) [9].
b The denominator is based on 37 patients with information on disease severity.
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Table 2
Results of Euroimmun SARS-CoV-2 IgG and IgA ELISAs on patient sera collected in 2019–2020 and specificity of these 
assays, Finland, 2020 (n = 37)
Description of samples positive for another virus than SARS-CoV-2
SARS-CoV-2 Euroimmun ratioa result 
 
(median ratio; range)





positive for the 
virus
IgG IgA IgG IgA
IgG 
 
(n = 26 individuals)























Influenza B virus (2019) 26
















































































Overall specificity 34/37 (91.9%)
27/37 
(73.0%)
No: number; NAT: nucleic acid test; RSV: respiratory syncytial virus; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.
a The ratios (between the extinction of the sample and calibrator) are the signals given by the assays. A ratio < 0.8 is considered negative, 
≥ 0.8 and < 1.1 inconclusive and ≥ 1.1 positive.
b The patient tested negative for SARS-CoV-2 nucleic acid.
c Of the five samples of human coronavirus OC43, four were collected in 2019 and one was collected in 2020. The sample from 2020 was from 
a patient, who was tested for SARS-CoV-2 nucleic acid and found negative.
d Same individual from year 2019.
Samples collected in 2019 were assumed to be from individuals who were not or had not been infected with SARS-CoV-2.
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To investigate the output of the immunoassays on 
samples from individuals who had been infected with 
SARS-CoV-2, we retrospectively collected serum sam-
ples from patients, who had been prior diagnosed 
with COVID-19 by real-time RT-PCRs (RT-qPCR) on naso-
pharyngeal samples as described by Corman et al. [6]. 
In total, 47 serum samples from 40 individuals (23 
males, 17 females) were included. The median age of 
the patients was 56 years (range: 24–77 years).
For 37 of these 40 individuals, a list of symptoms was 
available, enabling to rate their disease severity (Table 
1). The demographic characteristics of these patients 
are shown in Table 1 and their samples were employed 
to study serological results according to disease 
severity [9].
Finally, we used immunoassays to investigate 13 
sera of probable COVID-19 patients (according to 
the World Health Organization definition [10]) from 
February–March 2020, who had tested negative for 
SARS-CoV-2 by NAT.
Data were collected and samples handled according 
to research permit HUS/32/2018 (Helsinki University 
Hospital, Finland).
The specimens were analysed with SARS-CoV-2 IgG 
and IgA kits (Euroimmun) on the EUROLabworkstation 
(Euroimmun) platform.
Specificity of SARS-COV-2 IgG and IgA 
assays
From the panel of 37 sera considered negative for 
SARS-CoV-2, serologically negative results for IgG were 
found in 34 samples and for IgA in 27 samples, yielding 
a specificity of 91.9% for IgG and 73.0% for IgA (Table 
2). Serum samples from one patient with HCoV OC43 
infection showed a cross-reaction, however, cross-
reactions were not observed in patients with HCoV 
229E or NL63 infection.
Figure 1
Distribution of IgG and IgA ratio values (Euroimmun) from COVID-19 patients according to time after first positive PCR 
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Patient ID
COVID-19: coronavirus disease; ID: patient identification; RT-qPCR: real-time RT-PCR.
The ratio values (between the extinction of the sample and calibrator) are the signals given by the assays. A ratio < 0.8 is considered negative, 
≥ 0.8 and < 1.1 inconclusive and ≥ 1.1 positive. A dotted line indicates the 1.1 cut-off in the Figure.
The maximum IgG or IgA ratio value is 5 in this figure. Patient ID 12 is not included in the figure as the only serum sample was taken in January 
2020, 66 days before onset of symptoms.
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Results from confirmed COVID-19 patients
A total of 40 patients, whose serum samples were 
included in the study, had been diagnosed with COVID-
19 by RT-qPCR. One patient with a single sample taken 
before symptom onset was not further investigated. 
The IgG and IgA respective Euroimmun ratio values 
obtained from samples of the remaining 39 patients 
are shown relative to the time elapsed from the first 
positive PCR test result in Figure 1. It is notable, that for 
a patient with mild disease (ID 5) (Table 1), the serum 
sample was negative by IgG assay even 14 days after 
the first SARS-CoV-2 PCR-positive results (correspond-
ing to 16 days after onset of symptoms); this sample 
was nevertheless positive for IgA (Figure 1).
For 14 COVID-19 patients, a serum sample happened 
to have been collected on the same date as the naso-
pharyngeal sample used for SARS-CoV-2 RT-qPCR: 
none of the 14 serum samples showed IgG antibodies, 
while six showed IgA antibodies (Figure 2). The naso-
pharyngeal and serum samples were taken at a median 
of 5 days (range: 1–15) after onset of symptoms. 
Generally, IgA positivity seemed to be detected earlier 
than that of IgG and samples appeared more frequently 
positive with IgA than IgG (Figure 1, Figure 2).
Among the 39 COVID-19 patients screened for anti-
bodies against SARS-CoV-2, IgAs and IgGs were both 
detected in 13, while IgAs alone were detected in 11, 
yielding a total of 24 IgA positive patients. The median 
time after onset of symptoms was 12 days (13 patients 
range: 5–20 days) for detection of IgGs, and 11 days (24 
patients range: 5–20 days) for detection of IgAs (Figure 
3).
A total of 37 patients had, in addition to the date of 
symptom onset, a list of symptoms available, allow-
ing us to categorise the severity of their disease 
Figure 2
SARS-CoV-2 IgG and IgA ELISA ratio values (Euroimmun) and RT-qPCR Ct values from concurrent serum and 
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IgG and IgA cut-off
Days after onset of symptoms (+) 
Patient ID
Ratio value
Ct: cycle threshold; NA: not available; RT-qPCR: real-time RT-PCR; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.
The ratio values (between the extinction of the sample and calibrator) are the signals given by the assays. A ratio < 0.8 is considered negative, 
≥ 0.8 and < 1.1 inconclusive and ≥ 1.1 positive. A dotted line indicates the 1.1 cut-off in the figure.
For patient ID 21, the Ct value is above 40, but the RT-qPCR result was repeatedly positive and therefore the sample of this patient is 
considered to be PCR-positive.
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by COVID-19 as mild, moderate or severe [9] (Table 
1, Figure 3). We did not see any clear patterns between 
the IgG or IgA results and disease severity, however 
the patient number was low (Figure 3).
Results from probable COVID-19 patients
A number of individuals had returned from a COVID-19 
epidemic area in Europe or China and had fever and 
other symptoms compatible with respiratory infection, 
leading them to be considered as probable COVID-19 
patients, however their NAT on nasopharyngeal sam-
ples was negative for SARS-CoV-2 as well as for other 
respiratory viruses tested (Table 3). For 13 of these 
patients, concurrent nasopharyngeal and serum sam-
ples were available for serological testing: one patient 
was positive for both IgG and IgA in the serum sample, 
one patient for IgG alone, and one patient IgA alone 
(Table 3). No further samples from these patients were 
available for testing.
Discussion
Our results, albeit based on a small number of sam-
ples, showed a higher specificity of SARS-CoV-2 IgG 
ELISA (91.9%) than SARS-CoV-2 IgA ELISA (73.0%), 
therefore it is not suggested to use the IgA assay for 
initial screening. However, our results also indicate 
that the SARS-CoV-2 IgG ELISA (Euroimmun) with auto-
mated analysis and LIS can be used for screening of 
carefully targeted cohorts. Nevertheless, NAT should 
remain the method of choice for detection of acute 
SARS-CoV-2 infection.
In this study, serum samples from one patient with 
HCoV OC43 infection showed a cross-reaction in the 
SARS-CoV-2 immunoassays. The total number of HCoV 
samples was low (n = 7), but results are in line with 
the data reported by Okba et al. [7] and Amanat et al. 
[8]. Okba et al. [7] studied the specificity of IgG and 
IgA SARS-CoV-2 S1 ELISAs (research use only (RUO), 
Euroimmun) with 203 serum samples including 60 
serum samples (taken 2–4 weeks after onset of symp-
toms) from non-SARS HCoV cases (n = 23 OC43; n = 18 
NL63; n = 19 229E). Two HCoV OC43-positive samples 
cross-reacted in IgG and IgA assays, while HCoVs 
NL63 and 229E did not. In addition, these serum sam-
ples were also tested using a non-commercial Middle 
East Respiratory Syndrome coronavirus (MERS-CoV), 
S1 IgG ELISA [11] with similar cross-reactive results. 
Larger studies, including neutralisation assays, will be 
needed to further assess seroassay performance.
In our study, samples became IgA positive earlier than 
IgG, while the specificity of the test was lower for 
IgA. Considering the relatively slow IgG seroconver-
sion, a second convalescent sample is often needed 
to obtain reliable test results. In acute phase diag-
nostics, IgA assays could be useful along with IgG in 
patients presenting with atypical symptoms, or when 
RT-qPCR repeatedly remains negative in a suspected 
Figure 3
SARS-CoV-2 IgG and IgA ELISA ratio values (Euroimmun) from COVID-19 patients with data of disease severity and days 
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IgG or IgA cut-off
±Days after onset of symptoms  
Patient ID  
Disease severity  
ID: patient code.
The ratio values (between the extinction of the sample and calibrator) are the signals given by the assays. A ratio < 0.8 is considered negative, 
≥ 0.8 and < 1.1 inconclusive and ≥ 1.1 positive. A dotted line indicates the 1.1 cut-off in the figure.
The maximum IgG and IgA ratio value is 5 in this figure. Disease severity data were available from 37 of 40 COVID-19 patients (listed in Table 
1). Patient IDs 9, 11, and 18 not in this figure. In addition, patient ID 12 is not included in the figure as the only serum sample was taken in 
January 2020, 66 days before onset of symptoms.
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case. Nicastri et al. [12] reported a paucisymptomatic 
case with transient mild conjunctivitis and low fever 
with fluctuating PCR results. However, IgG response 
was detected when this case was isolated in the hos-
pital along with a positive PCR result. Haveri et al. [13] 
reported a patient with mild symptoms seroconverting 
(IgG) to SARS-CoV-2 in 9 days after onset of symptoms.
Okba et al. [7] reported that IgG and IgA kinetics var-
ied between patients with different disease severity. 
In that study, cases with a more severe disease devel-
oped an antibody response sooner and in higher con-
centrations. In our study, there were only 13 patients 
of 39 who were IgG positive with a median of 12 days 
(range: 5–20) after onset of symptoms and all 13 were 
also positive for IgA antibodies. The median for IgA 
alone (24 patients of 39) was 11 days (range: 5–20). As 
patient numbers were low, we cannot say if there was 
any clear pattern similar to the phenomenon observed 
by Okba et al. in our study, but we noted one case with 
mild disease severity (ID 5) who was still IgG negative 
16 days after onset of symptoms. However, this should 
be considered when interpreting the serological results 
for e.g. patients with mild disease.
Seroepidemiological studies will be very useful in 
informing public health measures in the coming 
months. In contrast, when attempting to retrospec-
tively establish diagnosis in clinical settings based on 
serology, it is of critical importance to carefully prese-
lect patients. Otherwise, the positive predictive value 
will be extremely low, and thus, not meaningful in the 
current epidemiological situation.
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